RPL24 and breast cancer: Given that RPL24 haploinsufficiency protects mice from Akt- and Myc-driven tumorigenesis [7, 8], it is interesting to note that at least 40% of basal-like breast cancers overexpress Akt or Myc [42], indicating that anti-RPL24 therapeutics could be effective against basal-like and other clinically aggressive subsets of human breast cancer.